Molecular results were as follows: one adenocarcinoma with EGFR mutation (L858R, exon 21) with remaining native biomarkers; one adenocarcinoma with NTRK mutation (NTRK3ex15) with remaining native biomarkers; six adenocarcinomas and one large cell neuroendocrine carcinoma with native EGFR, BRAF, ALK, ROS1, RET, MET, and NTRK. This evidence concerns the gene BRAF and adenocarcinoma.